Better Health for All

Eurofins' core business of analytical testing and laboratory services for food, pharmaceuticals, environmental, and consumer products ensures safety, quality, and compliance, providing exceptional health benefits. The company's revenue is derived from these services, indicating no products with negative health impacts. There is no evidence of direct user harm from the company's testing services. The Eurofins Foundation supported 73 projects in 2023, including emergency support for Turkey/Syria earthquake victims.

The company details various risk assessments and mitigation strategies in its report. Eurofins discusses environmental impact and waste management initiatives. The Eurofins Equality Driving Excellence (EDE) initiative focused on Unity in Community in 2023, including events, trainings, and projects. The company invested in training and talent development, including local trainings accessible via the Eurofins Learning Centre. The company mentions data security policies but provides no specific data on breaches or privacy safeguards. Eurofins assisted the Belgian government with PFAS blood testing for residents near a chemical production site. The company provides food testing services and initiatives related to organic farming. Eurofins mentions training programs on various health-related topics. The company does not conduct or sponsor clinical trials or health research.

Fair Pay & Worker Respect

Eurofins' employee engagement is reflected in a Glassdoor overall rating of 3.0 out of 5 and a 44% positive business outlook.

The company experienced mass layoffs in 2024, and multiple reviews from 2024-2025 mention a high turnover rate. In 2024, 47 reports were recorded via whistleblowing channels, with 32 cases investigated and 4 confirmed compliance breaches. In 2023, 3 confirmed compliance breaches resulted from 32 investigated reports. Some employees reported pay decreases when converting from temporary agency contracts, and there was a mass layoff in 2024. Women's representation in leadership roles grew to 36% in 2024, up from 30% in 2022, and 57% of all employees are women.

Honest & Fair Business

Eurofins reported zero ethics-related fines, penalties, or compensation for damages in 2024.

The company has a network-wide whistleblower protection program with guidelines and a reporting channel accessible via intranet and website, monitored by a third party to guarantee confidentiality and protect against retaliation. In 2024, 47 reports were recorded, 32 were investigated, and 4 resulted in confirmed compliance breaches with remedial action. Every Eurofins legal entity is audited annually by an independent financial audit firm, and special audits for corruption and bribery are conducted by internal and external auditors. The Board of Directors has 63% independent members. Eurofins has a strict anti-bribery and anti-corruption commitment, with a dedicated policy that applies to all Eurofins Companies, employees, and third parties. It prohibits facilitation payments and requires annual certifications from intermediaries. The ESG report is subject to independent review, and carbon credits are verified against recognized third-party standards.

Kind to Animals

Eurofins is a service-oriented company providing analytical testing and laboratory services. While the company offers vegan verification services

and emphasizes a commitment to the 3Rs (Replacement, Reduction, Refinement) of animal testing, detailing various in vitro methods for toxicology and biocompatibility, there is no specific quantitative data on the extent to which these non-animal methods are employed across its own operations or the percentage of tests that are animal-free. The company also provides contract research for veterinary pharmaceuticals, which includes pre-clinical and clinical studies, implying the use of animal testing. There is no information on the number of animals used annually, the percentage of R&D budget invested in animal-free technologies, or participation in multi-stakeholder initiatives with specific financial or resource commitments. The articles do not provide data on cruelty-free product certification, humane certifications for operations, wildlife conservation impact, ethical input substitution, supplier audits, cage-free sourcing, or public policy engagement related to animal welfare.

No War, No Weapons

Eurofins has a Sustainable Procurement Programme and a Group Supplier Code of Ethics that covers trade compliance, sanctions, export controls, and human rights.

In 2023, 58% of the company's purchasing spend was compliant with this code. Eurofins' policies incorporate a focus on ethical, social, and environmental aspects, with the United Nations Sustainable Development Goals in mind, and the company publicly cites UN Guiding Principles on Business and Human Rights (UNGP) alignment. However, no specific ethical 'red lines' banning involvement in arms manufacturing or conflict facilitation are mentioned in the provided articles.

Planet-Friendly Business

In 2024, Eurofins Scientific reported total Scope 1, 2, and 3 greenhouse gas emissions of 470,848 tCO₂e, representing a 3.8% reduction from 2023.

The company has also achieved a ~32% reduction in Scope 1, 2, and 3 CO2 emissions compared to its 2019 baseline. The company signed the SBTi commitment letter in early 2024, indicating that targets are pending validation. Globally, 27% of operational energy consumption came from renewables in 2024. The company announced a carbon neutrality goal by 2025. For waste, Eurofins BioPharma Product Testing US (EBPT US) achieved an 8% reduction in relative waste emissions year-over-year in 2023, and EBPT NA reduced absolute waste emissions by 21% compared to 2019 (US scope) and 25% year-over-year (Toronto) in 2024. The company has incurred $773,300 in environment-related penalties since 2000, with 18 records of environmental violations, including a $600,000 water pollution violation.

Respect for Cultures & Communities

Eurofins has at least 13 formal partnership agreements with indigenous or local community groups, including two with indigenous groups in Kenya and Brazil

, and multiple local partnerships in the US. The company reported no cultural appropriation incidents. Grievance mechanisms are available through local HR, a 24/7 whistleblowing point of contact in all languages, and a compliance helpline, with 46 whistleblowing reports in 2023. The Eurofins Learning Centre (ELC) is available in 16 languages , and the whistleblowing point of contact is available in all languages. In 2023, 15,442 employees completed the Eurofins Code of Ethics training , and equality training was rolled out globally in 2020.

Zero Waste & Sustainable Products

Eurofins has implemented several waste reduction initiatives, including a 21% reduction in absolute waste emissions at its US BioPharma Product Testing (EBPT) sites since 2019, and a 25% year-over-year reduction at its Canadian EBPT site.

The company's APAL division reduced waste relative emissions by 25% in 2023 through MIR spectral scanning. Eurofins Environment Testing in St. Louis saved 1.7 million gallons of water between 2022 and 2023 by reusing acid and base waste. The company has a target to become carbon neutral by 2025, which includes CO2 emission reduction projects. Eurofins conducts annual waste audits for major facilities, with Green Lab Ambassadors at Lancaster, PA, conducting regular audits. The company has strong supplier engagement, with 98% of its EBPT US Top 50 suppliers confirming adherence to Eurofins' Supplier Code of Ethics and/or sustainability commitments. However, Eurofins has faced challenges in hazardous waste management, with violations in 2013, 2020, and 2026, including mismanagement of contaminated paper filters. The company has also incurred multiple waste disposal violations, with a total of $28,000,464 in penalties since 2000, including a $600,000 water pollution violation in 2018.